Subsidiary of Zhejiang Hisun Pharmaceutical Obtains Veterinary Drug Approval

Stock News03-02

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has announced that its subsidiary, Zhejiang Hisun Animal Health Co., Ltd., recently received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the veterinary drug product Terbinafine Hydrochloride Tablets. Terbinafine Hydrochloride Tablets belong to the allylamine class of drugs and exhibit broad-spectrum antifungal activity. They are indicated for the treatment of canine skin infections caused by Microsporum canis. The mechanism of action involves specific interference with the early biosynthesis of fungal sterols, selectively inhibiting the fungal enzyme squalene epoxidase. This inhibition disrupts the squalene epoxidation reaction necessary for fungal cell membrane formation, leading to the eradication or suppression of the fungal infection.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment